- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1971. No additional regulatory steps are needed for the current indication.
- Why 3/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for M-M-R II in the next 12 months. The vaccine has been approved and marketed for over 50 years. It is also a small component of Merck's $65B+ annual revenue, which is dominated by Keytruda, Gardasil, and other products. Per the rubric, an approved drug with no pending regulatory decision scores 3-5, and the low end is appropriate given the drug's maturity and modest contribution to Merck's overall value.
M-M-R II has no scheduled binary catalysts. Merck investors should watch quarterly vaccine-segment revenue trends for signs of market-share erosion to GSK's Priorix, and monitor CDC/ACIP recommendation changes that could affect overall MMR vaccination rates. The more impactful near-term drivers for MRK stock are Keytruda patent-cliff dynamics, Gardasil sales trends, and pipeline readouts in oncology and cardiometabolic drugs.
Price Chart
Executive Summary
M-M-R II is Merck's long-established combination vaccine against measles, mumps, and rubella (MMR), first FDA-approved in 1971 and continuously marketed for over 55 years. It remains the most-sold MMR vaccine in the US, but faces growing competition from GSK's interchangeable rival Priorix (approved in the US in 2022). For a Merck investor, M-M-R II is a mature, steady-revenue product within a massive, diversified pharmaceutical business. It has no upcoming binary catalysts and represents a very small portion of Merck's valuation, which is dominated by Keytruda, Gardasil, and the broader pipeline.
How It Works
M-M-R II is a combination vaccine containing live, weakened (attenuated) versions of the measles, mumps, and rubella viruses. When injected, it stimulates the immune system to produce antibodies against all three viruses without causing the diseases themselves, providing long-term protection.
Trial Status
M-M-R II was first FDA-approved on April 22, 1971, and has been continuously marketed for over 55 years. It is the most-sold MMR vaccine in the United States, based on IQVIA and CDC data from June 2022 through December 2024. The vaccine is recommended by the CDC's Advisory Committee on Immunization Practices (ACIP) as a two-dose series at 12-15 months and 4-6 years of age.
The Two-Sided Case
Upcoming Catalysts
- None scheduled. M-M-R II is a mature, approved vaccine with no pending FDA decision, pivotal readout, or label-expansion catalyst in the next 12 months.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Merck & Co., Inc. 8-K MRK ·Originating report